1 |
Beuselinck B, Vano YA, Oudard S, et al (2014). Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int, 114, 81-9.
DOI
|
2 |
Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75.
DOI
|
3 |
Edesa WA, Abdelmalek RR (2015). Efficacy and toxicity of sunitinib in egyptian patients with metastatic renal cell carcinoma. Asian Pac J Cancer Prev, 16, 1971-76.
DOI
|
4 |
Gore ME, Szczylik C, Porta C, et al (2009). Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol, 10, 757-63.
DOI
|
5 |
Gore ME, Hariharan S, Porta C, et al (2011), Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 117, 501-9.
DOI
|
6 |
Kawai Y, Osawa T, Kobayashi K, et al (2015). Factors prognostic for survival in Japanese patients treated with sunitinib as first-line therapy for metastatic clear cell renal cell cancer. Asian Pac J Cancer Prev, 16, 5687-90.
DOI
|
7 |
Kim HS, Hong MH, Kim K, et al (2011). Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles. Oncol, 80, 395-405.
DOI
|
8 |
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17, 2530-40.
DOI
|
9 |
Krishna VM, Noronha V, Prabhash K, et al (2013). Sunitinib in metastatic renal cell carcinoma: A single center experience. Indian J Cancer, 50, 268-73.
DOI
|
10 |
Miyake H, Harada K, Miyazaki A, Fujisawa M (2015). Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. Med Oncol, 32, 78.
DOI
|
11 |
Motzer RJ, Bukowski RM (2006). Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol, 24, 5601-08.
DOI
|
12 |
Fujita T, Iwamura M, Ishii D, et al (2012). C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol, 19, 908-13.
DOI
|
13 |
Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24.
DOI
|
14 |
Powles T, Chowdhury S, Jones R, et al (2011). Sunitinib and other targeted therapies for renal cell carcinoma. Brit J Cancer, 104, 741-45.
DOI
|
15 |
Motzer RJ, Hutson TE, Tomczak P, et al (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 3584-90.
DOI
|
16 |
Najjar YG, Mittal K, Elson P, et al (2014). A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer, 50, 1084-9.
DOI
|
17 |
Negrier S, Escudier B, Lasset C, et al (1998). Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med, 338, 1272-78.
DOI
|
18 |
Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA (2003). Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res, 9, 4641-52.
|
19 |
Pantuck AJ, Seligson DB, Klatte T, et al (2007). Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer, 109, 2257-67.
DOI
|
20 |
Schnadig IA, Hutson TE, Chung H, et al (2014). Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in communitybased practices. Clinical Genitourinary Cancer, 12, 413-21.
DOI
|
21 |
Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics. CA Cancer J Clin, 64, 9-29.
DOI
|
22 |
Wagstaff J, Jones R, Hawkins R, et al (2016). Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol, 27, 159-65.
DOI
|